Clinical trialNCT06533826RecruitingPhase 2Interventional

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

SponsorAna C Garrido-Castro, MDEnrollment357Breast CancerHER2-low Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ana Garrido-Castro, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama
Birmingham, Alabama, United States
Humaira Sarfraz, MD
Recruiting
University of San Francisco
San Francisco, California, United States
Laura Huppert, MD
Recruiting
Yale University Cancer Center
New Haven, Connecticut, United States
Maryam Lustberg, MD, MPH
Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Candace Mainor, MD
Recruiting
University of Chicago Medical Center
Chicago, Illinois, United States
Nan Chen, MD
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Shana Berwick, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Ana Garrido-Castro, MD
Recruiting
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States
Jesus Anampa, MD
Recruiting
University of North Carolina
Chapel Hill, North Carolina, United States
Yara Abdou, MD
Recruiting
Vanderbilt Cancer Center
Nashville, Tennessee, United States
Vandana Abramson, MD
Recruiting
Baylor College of Medicine
Houston, Texas, United States
Ahmed Elkhanany, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Datopotamab deruxtecan →Trastuzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Oct 2024
Primary completion: 1 Jan 2028
Completion: 1 Aug 2038
Last update posted: 24 Oct 2025
Registered enrollment: 357
Registry id: NCT06533826

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.